Bli medlem
Bli medlem

Du är här

2021-04-07

Guard Therapeutics obtains a granted patent from USPTO concerning ROSgard as product

Guard Therapeutics AB (publ.) today announces that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application no. 16/085,500 directed to the biological investigational drug ROSgard as product (composition of matter). The granted patent follows the Notice of Allowance that was issued and communicated in December 2020.

The granted patent will issue as US patent no. 10,981,963 on 20 April 2021 and protects Guard Therapeutics’ lead investigational drug ROSgard as a product. The patent, which provides protection until 2037, also covers related molecules that are of similar structure to ROSgard. The granted patent further strengthens Guard Therapeutic’s patent portfolio and the commercial potential of ROSgard.
 
“With the USPTO granting this patent, Guard Therapeutics has obtained a valuable patent protection for ROSgard as a product in the US, one of the company’s projected key markets. The patent is an important part of the company’s integrated patent portfolio and supports the continued development of our investigational drug ROSgard” Tobias Agervald, CEO of Guard Therapeutics says.

For further information, please contact:


Tobias Agervald, CEO
Telephone: +46 46 286 50 30
E-mail: info@guardtherapeutics.com 

About Guard Therapeutics


Guard Therapeutics is a pharmaceutical company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s clinical investigational drug ROSgard is being developed as a protective treatment against acute kidney injury with an initial focus on patients undergoing heart surgery. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, ca@skmg.se.

Attachments


Guard Therapeutics obtains a granted patent from USPTO concerning ROSgard as product

Författare MFN

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.